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Drug information for patients - an update of long-term results:
type of enquiries and patient characteristics
Abstract
PURPOSE: To analyse the type of enquiries to a drug information service in Germany, available
exclusively for patients. METHODS: Sociodemographic characteristics of the patients who used the
service, number and kind of drugs taken, existing diseases, reasons for enquiry as well as type of
answers provided were recorded. For the present evaluation we analysed all enquiries to the service
from August 2001 to January 2007. RESULTS: A total of 5587 enquiries were received. 5013 enquiries
from 4091 patients were available for further analysis in detail. The patient group using the service most
frequently were women between 61 and 70 years (23.3%). 1457 enquiries (29.1%) were made by
patients who had contacted the information service once or several times before. The group of drugs
most often asked about were cardiovascular drugs (33.4%), followed by drugs for the nervous system
(16.2%) and for the alimentary tract and metabolism (12.4%). On average, each patient had questions
about 2.6 (median 1; 1-22) drugs simultaneously. Common reasons for contacting the service were
adverse drug reactions (22.1%), the need for general information about the drug (19.9%), information
about therapy (12.4%) and drug interactions (10.2%). CONCLUSIONS: A lot of patients need
additional information about their medication, especially concerning drug groups that are frequently
prescribed. The presented drug information service can be one helpful tool to counteract these
information deficits and to increase patients' knowledge about their drugs.
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Abstract 
Purpose 
To analyse the type of enquiries to a drug information service in Germany, available 
exclusively for patients. 
Methods 
Sociodemographic characteristics of the patients who used the service, number and kind of 
drugs taken, existing diseases, reasons for enquiry as well as type of answers provided were 
recorded. For the present evaluation we analysed all enquiries to the service from August 
2001 to January 2007.  
Results 
A total of 5587 enquiries were received. 5013 enquiries of 4091 patients were available for 
further analysis in detail. The patient group using the service most frequently were women 
between 61 and 70 years (23.3%). 1457 enquiries (29.1%) were made by patients who had 
contacted the information service once or several times before. The group of drugs most often 
asked about were cardiovascular drugs (33.4%), followed by drugs for the nervous system 
(16.2%) and for the alimentary tract and metabolism (12.4%). On average, each patient had 
questions about 2.6 (median 1; 1-22) drugs simultaneously. Common reasons for contacting 
the service were adverse drug reactions (22.1%), the need for general information about the 
drug (19.9%), information about therapy (12.4%) and drug interactions (10.2%).  
Conclusions 
A lot of patients need additional information about their medication, especially concerning 
drug groups that are frequently prescribed. The presented drug information service can be one 
helpful tool to counteract these information deficits and to increase patients’ knowledge about 
their drugs. 
Key words  
Drug information service – patients – age distribution – type of enquiry 
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Introduction 
Safety is an essential principle of patient care; therefore, the Fifty-fifth World Health 
Assembly underlined the importance of promoting science-based systems to improve patient 
safety and the quality of health care, including the safe use of medicinal products.
1
 
Medication errors and adverse drug reactions not only have an impact on human health but, 
are also a significant financial burden on the health care system.
2,3
 The high costs due to these 
events show the necessity of prevention, e.g. through educational programmes, to save money 
and to improve the quality of care.
2,3
 Dietary supplements, which are frequently regarded as 
harmless and safe by the patients, can be associated with adverse events, too.
4,5
  
Deficiencies in system design, organisation and operation are primarily seen as the reasons 
leading to adverse events, and the individual physician may only contribute to a lesser extent.
6
 
As the average length of consultation in a German general practitioner’s office is less than 8 
minutes, the limited time with the doctor could be one aspect inherent to the health care 
system.
7,8
 Misinterpretation of the advice given by the physician or pharmacist, or insufficient 
provision of required information about the medication, may result in decreased compliance 
of the patient.
9
 However, patient education and counselling are of prime importance to 
improve compliance, as a well-informed patient is the key to ensure taking the drugs 
prescribed.
10
 In particular those patients with multiple drugs have the need for adequate 
information, as they are more likely to be noncompliant.
11
 
As one resource, patients try to inform themselves about their medication and diseases using 
the internet,
12
 but the quality of websites about drugs and health-related topics varies widely,
13
  
and not authentificated information might be associated with some dangers.
14
 The patient 
package insert of a drug could be another – and reliable – source of information. Literature 
data, however, suggest that patients do not understand its meaning, and that personal 
recommendations of a physician or pharmacist are more helpful and better accepted.
15
 This is 
in accordance with identified preferences of patients for a patient-centred consultation 
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including communication.
16
  
Drug information services managed by health care professionals can be a helpful tool to 
answer medication-related questions and to provide general information about drugs.
17
 Such 
centres addressing physicians and pharmacists have existed in Germany for a long time, and 
their usefulness has been demonstrated.
18,19
 In 2001, a drug information service was 
established in Dresden, Germany, available exclusively for patients.
20,21
 For the present paper 
we evaluated all enquiries to this service within 6 years. The objectives were to analyse the 
type of enquiries as well as answers provided by the drug information service. Finally, the 
kind of information need on the patient side should be identified. 
 
Methods 
The drug information service for patients (DISP) – located at the Institute of Clinical 
Pharmacology, Faculty of Medicine of the Technische Universität Dresden, Germany, and 
financed by the German Head Associations of Health Insurance Funds according to §65b of 
Social Code Book V – has been operating since 2001. The service was initially organised for 
patients in the area of Saxony, and was repeatedly advertised in media (print, radio, 
television). Since 2005 enquiries from all over Germany have been accepted. The DISP was 
free of charge for the enquiring person to prevent disadvantages towards persons with lower 
income, and independent as regards content. The consultation of the patients was managed by 
pharmacists and clinical pharmacologists. The Institute of Clinical Pharmacology has already 
had experience with a drug information service for office-based physicians in Saxony, 
existing since 1995.
22,23,24
  
 
Operation of the DISP 
The DISP was available by telephone during office hours from Monday to Friday. The initial 
phone call was answered by skilled staff members of the institute. Outside of office hours, 
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patients had the possibility to leave a message on an answering machine, send an e-mail or a 
regular mail. All enquiries were documented using a standardised drug consultation form that 
had been specially created for the DISP. Sociodemographic characteristics (age, gender, 
geographical region etc.) were recorded, also complete medication as well as existing diseases 
of the patients, and in addition which of these drugs and diseases had caused the enquiry. 
Classification of drugs was made according to the Anatomical Therapeutic Chemical (ATC) 
classification system (WHO Collaborating Centre for Drug Statistics Methodology, Oslo, 
Norway). The patient-reported diseases were categorised using the International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10, World Health 
Organization, Geneva, Switzerland). Furthermore, the reasons for an enquiry were recorded. 
These were classified into appropriate categories, e.g. adverse drug reactions, drug 
interactions, information about therapy, application or dosage of the drug). 
The enquiry was transmitted to an adviser (pharmacist or clinical pharmacologist) and 
answered after an investigation period. The summary of medicinal product characteristics of 
the respective drug, the international drug databases DRUGDEX® and DRUG-REAX® 
System (Thomson Healthcare, Greenwood Village, CO, USA) as well as current guidelines of 
German and international medical associations were commonly used as sources of 
information. For complex problems experts from the University Hospital Dresden were 
consulted. Answers were primarily given by telephone, because only a personal conversation 
enables to directly respond to the needs and expectations of the enquiring person. The patients 
were informed that the advice provided by the DISP can only be general information about 
drugs and is not a treatment recommendation. In addition, patients were regularly encouraged 
to consult their attending physician. The types of answer provided by the DISP were 
documented on the drug consultation form. The time to answer an enquiry (investigation and 
counselling the patient) was recorded, too. 
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Analyses 
All enquiries including answers were stored in a relational database using Microsoft Access 
2003 (Microsoft Corporation, Redmond, WA, USA). For the present evaluation the data of 
each enquiry to the DISP between August 2001 and January 2007 were analysed. Due to 
study design approval by an institutional or national ethics committee was not required 
according to German law. 
Statistical comparison of categorical variables was performed using chi-square test. 
Continuous variables were compared with t-test and Mann-Whitney U-test. For all tests a 
two-sided p-value below 0.05 was considered significant. All statistical analyses were 
performed using SPSS 15.0.1 (SPSS Inc., Chicago, IL, USA).  
 
Results 
Patient characteristics 
During the analysed period (August 2001 to January 2007), a total of 5587 enquiries were 
registered. Figure 1 shows the monthly number of all enquiries, which varied widely over 
time; on average, there were 85 enquiries per month. Restricting analysis to those enquiries 
for which age and gender of the patient were known, 5013 enquiries of 4091 individuals were 
available for further evaluation. 35.5% (n = 1451) of the patients were male, 64.5% (n = 
2640) female, the mean age was 61.5 (SD 14.9) years (men: 62.5 (SD 15.0), women: 60.9 
(SD 14.8); p = 0.002). The majority of patients were older than 60 (n = 2621, 64.1%). The 
largest group were women between 61 and 70 years (n = 955, 23.3% of patients). A higher 
proportion of female individuals could be found in each age group. Two thirds of the patients 
originated from Saxony, the geographical area around Dresden (men: 66.9%, n = 970; 
women: 69.9%, n = 1845). In 85.2% (n = 4272) of the enquiries, patients contacted the DISP 
by themselves, whereas 14.8% (n = 741) of the enquiries were managed via a third person 
(e.g. spouse, child of the patient).  
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In 4914 enquiries, drugs were indicated by the patients. On average, men took significantly 
more drugs than women (5.5 (SD 3.6) vs. 4.9 (SD 3.3); p < 0.001), patients older than 60 
years significantly more than patients less than or equal to 60 years of age (5.8 (SD 3.5) vs. 
3.9 (SD 2.9); p < 0.001). Existing diseases of the patients were reported in 4849 enquiries. No 
significant difference concerning mean number of diseases was found between male and 
female (3.0 (SD 1.9) vs. 2.9 (SD 1.7); p = 0.388). However, the age had an impact (>60 years: 
3.2 (SD 1.8) vs. ≤60 years: 2.4 (SD 1.5); p < 0.001). 535 patients contacted the DISP more 
than once, causing 1457 (29.1%) enquiries (Table 1). There was no significant difference in 
gender distribution between single and repeat enquiries (p = 0.674).  
 
Content of enquiries 
Table 2 gives an overview of the drug and disease groups that caused an enquiry. 4914 of the 
5013 enquiries analysed were drug-related. Cardiovascular drugs (ATC group C) clearly 
dominated with 33.4% (n = 4269), followed by drugs for the nervous system (ATC group N) 
with 16.2% (n = 2066). Substances enquired about without ATC code included dietary 
supplements, homoeopathics and medical devices, and were ranked fourth (7.5%, n = 954). It 
is noteworthy that only a total of 7.8% (n = 1000) of all drugs asked about were bought by the 
patients without prescription, including 710 dietary supplements – which were ranked sixth 
with 5.6% if regarded as separate category.  
On average, 2.6 (median 1; 1-22) drugs were asked about per enquiry, significantly more 
drugs by male than by female patients (2.9 (median 1; 1-21) vs. 2.4 (median 1; 1-22); p < 
0.001). The mean number of medicines enquired about increased with the age of the patient. 
Drugs for the cardiovascular system were more frequently stated as the reason for the enquiry 
by men as well as by patients older than 60 years (39.3% and 37.2%, respectively), than by 
women (29.5%) or patients less than/equal to 60 years (≤40: 12.7%, 41-60: 26.5%). However, 
drugs for the nervous system were more often asked about by younger individuals (≤40 years: 
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25.4%, 41-60 years: 20.0%, >60 years: 14.2%). The number of drugs taken by the patient had 
an impact, too, in particular on the frequency of enquiries about cardiovascular drugs (≤4 
drugs taken: 26.8%, >4 drugs taken: 36.0%). 
In 3339 enquiries, diseases were stated by the patients as responsible for the question to the 
DISP (Table 2). Diseases of the circulatory system (19.5%, n = 702) most frequently caused 
an enquiry. 
Common reasons leading patients to contact the DISP were, as presented in Table 3, adverse 
drug reactions (22.1%, n = 2177), the need for general information about the drug (19.9%, n = 
1964), information about therapy (12.4%, n = 1221) and drug interactions (10.2%, n = 1002).  
On average, there were 2.0 reasons for an enquiry of a patient. As additional cause, lack of 
available time of the attending physician was stated in 238 enquiries. Furthermore, each drug 
asked about was linked with the reasons for the question. Drugs for the blood and blood 
forming organs as well as for the cardiovascular system were more likely to be associated 
with enquiries about adverse drug reactions (25.4% and 25.9%, respectively) and drug 
interactions (19.8% and 18.0%, respectively). The 99 enquiries in which no drug was 
mentioned by the patients were mainly related to questions about treatment options in general. 
 
Type of information provided by the DISP 
Table 4 shows the types of answer which were given by the DISP during consultations. As the 
answers provided were dealing with the individual problems of the patients in a more detailed 
way, the totalled number was higher than the number of reasons leading to an enquiry. 
General information about the drug was most frequently given as answer (24.4%, n = 3000). 
Advice concerning adverse drug reactions was in the second place, accounting for 14.8% (n = 
1827). In 1453 consultations patients were encouraged to visit a physician for discussing their 
drug-related problem. The average time to answer an enquiry (investigation and counselling 
the patient) was 26.7 (SD 17.5) minutes (data were not available for 187 enquiries).  
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Discussion 
In the analysed period, the DISP was frequently contacted by patients, indicating an existing 
need for additional information about their medication. There was a wide fluctuation in the 
monthly number of enquiries to the service over time. Advertising in print media as well as 
via radio or television highly increased the number of questions.  
The majority of enquiring patients were older than 60 years. As the number of drugs 
prescribed increases with age,
25,26
 and polypharmacy is associated with a higher risk for 
several health problems (e.g. adverse drug reactions),
27
 a greater need for medication-related 
information among the elderly may have been the underlying reason. In addition, more 
women than men used the DISP, possibly due to their higher proportion in the older 
population.
28
 As this, however, does not explain the imbalance between male and female 
among younger patients, another factor could have been that women are more likely to use 
external help than men.
29
 Reports on drug information services in other countries showed a 
gender distribution comparable to our findings.
30,31,32
 As expected, patients contacting the 
service more than once were older, had to take more drugs or were suffering from more 
diseases, which increased the number of medication-related questions. On average, men asked 
about significantly more drugs per enquiry than women, correlating with a larger number of 
drugs taken. Their higher mean age may have been responsible, because older age is generally 
associated with an increased medication use.
25,26
 In addition, the number of drugs prescribed 
to older men slightly exceeds that prescribed to older women.
26
  
The distribution of the drug groups enquired about was paralleled by national prescription 
figures, for the year 2006 see Table 5, with few exceptions (e.g. antibacterials for systemic 
use/ATC group J01).
33
 Drugs for the cardiovascular system were most commonly prescribed 
in the analysed period,
33,34
 and they were most often stated by the patients as reason for an 
enquiry – more frequently by older as well as male individuals, which is in accordance with 
findings from the literature, too.
25
 Moreover, as mental disorders are highly prevalent in the 
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German population,
35
 a lot of questions were about drugs for the nervous system. In general, 
the medication asked about correlated with the patient-reported diseases. However, as 
diseases of the circulatory system are usually treated with a combination of multiple agents, 
the proportion of cardiovascular drugs was substantially higher. The fact that the majority of 
questions were related to frequently prescribed drugs, and not only to those with special 
pharmacological characteristics, may argue for a general information need. Furthermore, the 
number of dietary supplements enquired about – taken by the patients without consultation of 
a doctor – was notable. Limited product information might lead to misconceptions about the 
effects of these substances.
36
 Therefore, drug information centres can be useful as a valuable 
source of information.
37
 
Adverse drug reactions are common reasons for contacting a drug information service,
31,32,38
 
which was also observed in our evaluation of the DISP, and are of particular relevance for 
patient safety. Adverse drug reactions are responsible for an increasing number of hospital 
admissions in recent years.
39
 Certain drugs, e.g. for the blood and blood forming organs or for 
the cardiovascular system, are more likely to be associated with serious adverse events.
40
 As a 
considerable number of adverse drug reactions leading to hospitalisation is regarded as 
avoidable – especially in older individuals – appropriate prevention is needed.40 Sufficient 
information of the patient could be one important measure.  
In addition, patients who experienced adverse drug reactions are more likely to be 
noncompliant.
41
 On the other hand, adequate consultation on the prescribed drugs and the 
concept of therapy leads to increased compliance.
41
 For this purpose, distance medicine 
technology (e.g. telephone counselling as provided by the DISP) can be one useful instrument 
which has shown benefits for the patients.
42
 Consultations by phone are highly accepted due 
to convenience,
43
 and may reduce the use of medical care – implicating potential cost saving 
effects.
44
 
The intention of the DISP was not to substitute the face-to-face consultation with the treating 
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physician, who knows most of the patient and his medical history, and who should be the 
primary responsible for providing comprehensive information about the use of medication. 
However, the service was supportive whenever there were any further questions on the 
patients’ side. As mostly self-motivated individuals are addressed by a telephone-based drug 
information service, further research is needed to determine how to reach other patient 
groups.
31
 
The advice provided by the DISP could only be given within the context of patients’ self-
reported information about their drugs and diseases. This is a limitation of an independent and 
telephone-based drug information service, as it was not possible to verify patients’ statements 
with medical records kept by attending physicians. However, there is evidence from the 
literature that self-reports by patients are reliable when compared to objectively obtained 
data.
45
  
 
Conclusion 
The findings that emerge from our experience with a drug information service for patients 
demonstrate an existing need on the patient side for additional counselling about the 
medication. In particular frequently prescribed drugs were enquired about, which may 
indicate an information need not only for drugs with special pharmacological characteristics. 
Medical advice given by telephone may serve as an additional source of drug-related 
information for patients. Therefore, the DISP can be one helpful tool to counteract 
information deficits and to increase patients’ knowledge about their medication. 
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Key points 
 A lot of patients need additional information about their medication.  
 The drug information service for patients can be a useful instrument to counteract deficits 
in drug-related knowledge.  
 Enquiries were mainly related to frequently prescribed medication, such as drugs for the 
cardiovascular system, for the nervous system or for the alimentary tract and metabolism.  
 Adverse drug reactions were the most common reason for contacting the service. 
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Legends to figures and tables (in order of appearance in the text) 
Figure 1 
Number of all enquiries to the drug information service for patients per month in the period 
from August 2001 to January 2007 
 
Table 1 
Differences in patient characteristics between single and repeat enquiries 
 
*Percentages may not add exactly to 100.0 due to rounding error. 
 
Table 2 
Drugs and diseases that caused an enquiry, classified according to ATC system and ICD-10, 
respectively. More than one drug/disease could be mentioned by the patient. Data are 
presented for all enquiries and for different patient groups 
 
ATC, Anatomical Therapeutic Chemical; ICD-10, International Statistical Classification of 
Diseases and Related Health Problems 10th Revision. 
*Values for dietary supplements are not added to the total sum as they are included in 
"Substances without ATC code". 
**Percentages in several columns do not add exactly to 100.0 due to rounding error. 
***Based on 4914 enquiries. 
+
Certain disorders involving the immune mechanism. 
++
Based on 3339 enquiries. 
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Table 3 
Reasons that led patients to contact the drug information service, shown for all enquiries in 
general, and linked with different major groups of drugs asked about (according to ATC 
classification system). More than one reason for an enquiry could be indicated 
 
ATC, Anatomical Therapeutic Chemical; A, alimentary tract and metabolism; B, blood and 
blood forming organs; C, cardiovascular system; G/H, genito urinary system and sex 
hormones/systemic hormonal preparations, excluding sex hormones and insulins; J/L, 
antiinfectives for systemic use/antineoplastic and immunomodulating agents; M, musculo-
skeletal system; N, nervous system. 
*Substances without ATC code, including dietary supplements. 
**Percentages in several columns do not add exactly to 100.0 due to rounding error. 
 
Table 4 
Types of answer provided by the drug information service. More than one category per 
enquiry was possible 
 
*Percentages do not add exactly to 100.0 due to rounding error. 
 
Table 5 
The 12 most frequently prescribed drug groups in Germany (at the expense of the Statutory 
Health Insurance),
33
 compared with the percentages of the respective drug groups asked about 
by the patients, in the year 2006 (classified according to ATC system) 
 
ATC, Anatomical Therapeutic Chemical; SHI, Statutory Health Insurance; DISP, drug 
information service for patients 
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Figure 1 
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Table 1 
  Single enquiries Repeat enquiries p-value 
  n % n %   
      Total* 3556 100.0 1457 100.0 
 Gender 
    
0.674 
   Male 1267 35.6 510 35.0 
    Female 2289 64.4 947 65.0 
 Age, years 
    
<0.001 
   ≤40 378 10.6 117 8.0 
    41-60 923 26.0 336 23.1 
    >60 2255 63.4 1004 68.9 
 Number of drugs taken 
    
<0.001 
   ≤4 1912 53.8 692 47.5 
    >4 1644 46.2 765 52.5 
 Number of patient-reported diseases 
    
0.002 
   0-1 919 25.8 347 23.8 
    2-3 1616 45.4 617 42.3 
    >3 1021 28.7 493 33.8   
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Table 2 
    All enquiries   Gender p-value Age, years p-value Number of drugs taken p-value 
  
    
 
Male Female 
 
≤40 41-60 >60 
 
≤4 >4 
 
    n %   n % n %   n % n % n %   n % n %   
                      
Drugs, ATC group 
       
<0.001 
      
<0.001 
    
<0.001 
   A Alimentary tract and metabolism 1579 12.4 
 
642 12.5 937 12.2 
 
73 8.6 301 11.4 1205 13.0 
 
387 10.6 1192 13.0 
 
   B Blood and blood forming organs 780 6.1 
 
368 7.2 412 5.4 
 
33 3.9 119 4.5 628 6.8 
 
140 3.8 640 7.0 
 
   C Cardiovascular system 4269 33.4 
 
2010 39.3 2259 29.5 
 
107 12.7 699 26.5 3463 37.2 
 
978 26.8 3291 36.0 
 
   G Genito urinary system and sex hormones 521 4.1 
 
236 4.6 285 3.7 
 
64 7.6 139 5.3 318 3.4 
 
223 6.1 298 3.3 
 
   H Systemic hormonal preparations, excluding sex hormones and insulins 439 3.4 
 
94 1.8 345 4.5 
 
37 4.4 124 4.7 278 3.0 
 
144 3.9 295 3.2 
 
   J Antiinfectives for systemic use 229 1.8 
 
66 1.3 163 2.1 
 
68 8.0 55 2.1 106 1.1 
 
124 3.4 105 1.1 
 
   L Antineoplastic and immunomodulating agents 263 2.1 
 
60 1.2 203 2.6 
 
19 2.2 102 3.9 142 1.5 
 
126 3.5 137 1.5 
 
   M Musculo-skeletal system 856 6.7 
 
278 5.4 578 7.5 
 
43 5.1 185 7.0 628 6.8 
 
252 6.9 604 6.6 
 
   N Nervous system 2066 16.2 
 
771 15.1 1295 16.9 
 
215 25.4 527 20.0 1324 14.2 
 
658 18.0 1408 15.4 
 
   R Respiratory system 441 3.4 
 
169 3.3 272 3.5 
 
73 8.6 89 3.4 279 3.0 
 
104 2.9 337 3.7 
 
   S Sensory organs 154 1.2 
 
58 1.1 96 1.3 
 
11 1.3 34 1.3 109 1.2 
 
61 1.7 93 1.0 
 
   Other ATC groups 232 1.8 
 
72 1.4 160 2.1 
 
40 4.7 62 2.4 130 1.4 
 
119 3.3 113 1.2 
 
   Substances without ATC code 954 7.5 
 
292 5.7 662 8.6 
 
62 7.3 199 7.6 693 7.4 
 
330 9.1 624 6.8 
 
 
including dietary supplements* 710 5.6 
 
225 4.4 485 6.3 
 
29 3.4 137 5.2 544 5.8 
 
223 6.1 487 5.3 
 
Total** 
 
12783 100.0 
 
5116 100.0 7667 100.0 
 
845 100.0 2635 100.0 9303 100.0 
 
3646 100.0 9137 100.0 
 
Mean (median; min-max)*** 2.6 (1; 1-22) 
 
2.9 (1; 1-21) 2.4 (1; 1-22) 
 
1.8 (1; 1-12) 2.1 (1; 1-22) 2.9 (1; 1-21) 
 
1.5 (1; 1-4) 3.8 (2; 1-22) 
 
                      
Diseases, ICD-10 group 
       
<0.001 
      
<0.001 
    
0.001 
   C/D Neoplasms/diseases of the blood and blood-forming organs and immune mechanism
+
 163 4.5 
 
53 4.3 110 4.6 
 
7 1.7 55 5.7 101 4.5 
 
108 5.5 55 3.4 
 
   E Endocrine, nutritional and metabolic diseases 455 12.7 
 
186 15.3 269 11.3 
 
14 3.5 119 12.4 322 14.4 
 
246 12.6 209 12.8 
 
   F Mental and behavioural disorders 290 8.1 
 
101 8.3 189 8.0 
 
75 18.7 102 10.7 113 5.1 
 
163 8.3 127 7.8 
 
   G Diseases of the nervous system 220 6.1 
 
80 6.6 140 5.9 
 
26 6.5 66 6.9 128 5.7 
 
111 5.7 109 6.7 
 
   H Diseases of the eye and adnexa/diseases of the ear and mastoid process 131 3.6 
 
41 3.4 90 3.8 
 
9 2.2 33 3.4 89 4.0 
 
74 3.8 57 3.5 
 
   I Diseases of the circulatory system 702 19.5 
 
260 21.3 442 18.6 
 
23 5.7 156 16.3 523 23.4 
 
351 18.0 351 21.4 
 
   J Diseases of the respiratory system 163 4.5 
 
55 4.5 108 4.6 
 
44 11.0 34 3.6 85 3.8 
 
89 4.6 74 4.5 
 
   K Diseases of the digestive system 204 5.7 
 
70 5.7 134 5.6 
 
17 4.2 52 5.4 135 6.0 
 
113 5.8 91 5.6 
 
   L Diseases of the skin and subcutaneous tissue 106 3.0 
 
47 3.9 59 2.5 
 
32 8.0 20 2.1 54 2.4 
 
65 3.3 41 2.5 
 
   M Diseases of the musculoskeletal system and connective tissue 480 13.4 
 
113 9.3 367 15.5 
 
23 5.7 115 12.0 342 15.3 
 
237 12.1 243 14.8 
 
   N Diseases of the genitourinary system 194 5.4 
 
78 6.4 116 4.9 
 
21 5.2 66 6.9 107 4.8 
 
124 6.3 70 4.3 
 
   Other ICD-10 groups 484 13.5 
 
135 11.1 349 14.7 
 
110 27.4 139 14.5 235 10.5 
 
273 14.0 211 12.9 
 
Total** 
 
3592 100.0 
 
1219 100.0 2373 100.0 
 
401 100.0 957 100.0 2234 100.0 
 
1954 100.0 1638 100.0 
 
Mean (median; min-max)
++
 1.1 (1; 1-4)   1.1 (1; 1-3) 1.1 (1; 1-4)   1.1 (1; 1-4) 1.1 (1; 1-3) 1.1 (1; 1-4)   1.0 (1; 1-4) 1.1 (1; 1-4)   
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Table 3 
  All enquiries   Enquiries about drugs, ATC group 
 
    
 
A B C G/H J/L M N Other ATC groups No ATC code* 
  n %   n % n % n % n % n % n % n % n % n % 
                      
Adverse drug reactions 2177 22.1 
 
649 21.8 379 25.4 2126 25.9 430 23.1 219 22.4 405 23.5 1008 24.0 334 21.0 293 15.3 
General information about drug 1964 19.9 
 
595 20.0 315 21.1 1755 21.4 405 21.7 224 22.9 387 22.4 866 20.6 315 19.8 382 20.0 
Information about therapy 1221 12.4 
 
292 9.8 137 9.2 842 10.3 216 11.6 163 16.7 189 11.0 522 12.4 201 12.6 173 9.1 
Drug interactions 1002 10.2 
 
460 15.5 295 19.8 1481 18.0 286 15.4 106 10.8 266 15.4 660 15.7 203 12.8 225 11.8 
Indication/contraindication of drug 854 8.7 
 
263 8.8 132 8.9 649 7.9 162 8.7 105 10.7 164 9.5 356 8.5 169 10.6 164 8.6 
Costs/refund/prescription requirement/drug-related legislation 719 7.3 
 
328 11.0 58 3.9 242 2.9 114 6.1 16 1.6 71 4.1 157 3.7 127 8.0 85 4.4 
Self-medication/dietary supplements/alternative medicine/medical devices 545 5.5 
 
112 3.8 34 2.3 189 2.3 49 2.6 15 1.5 71 4.1 97 2.3 55 3.5 410 21.5 
Application/dosage of drug 433 4.4 
 
117 3.9 65 4.4 365 4.4 72 3.9 44 4.5 54 3.1 194 4.6 50 3.1 76 4.0 
Change of medication 371 3.8 
 
50 1.7 29 1.9 289 3.5 53 2.8 15 1.5 59 3.4 144 3.4 23 1.4 22 1.2 
Mechanism of drug action/pharmacokinetics 188 1.9 
 
32 1.1 14 0.9 99 1.2 15 0.8 29 3.0 27 1.6 44 1.0 24 1.5 30 1.6 
Pregnancy/breastfeeding 94 1.0 
 
14 0.5 8 0.5 12 0.1 23 1.2 16 1.6 7 0.4 13 0.3 30 1.9 12 0.6 
Other topics not categorised elsewhere 295 3.0 
 
60 2.0 25 1.7 162 2.0 38 2.0 25 2.6 24 1.4 141 3.4 58 3.7 39 2.0 
Total** 9863 100.0   2972 100.0 1491 100.0 8211 100.0 1863 100.0 977 100.0 1724 100.0 4202 100.0 1589 100.0 1911 100.0 
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Table 4 
  n % 
   General information about drug 3000 24.4 
Adverse drug reactions 1827 14.8 
Information about therapy 1702 13.8 
Drug interactions 825 6.7 
General need for information 614 5.0 
Costs/refund/prescription requirement 530 4.3 
Change of medication 508 4.1 
Mechanism of drug action 492 4.0 
Indication of drug 477 3.9 
General rules of conduct concerning drug 390 3.2 
Information about self-medication 378 3.1 
Dietary supplements 291 2.4 
Dosage correction 268 2.2 
Application of drug 238 1.9 
Drug-related legislation 190 1.5 
Contraindication 156 1.3 
Pharmacokinetics 88 0.7 
Alternative medicine 82 0.7 
Pregnancy/breastfeeding 60 0.5 
Generics 28 0.2 
Availability of drug 27 0.2 
Eating habit 26 0.2 
Medical devices 20 0.2 
Other topics not categorised elsewhere 102 0.8 
Total* 12319 100.0 
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Table 5 
ATC group SHI DISP 
    % % 
      
C09 Agents acting on the renin-angiotensin system  7.0 9.1 
   
J01 Antibacterials for systemic use  6.5 1.2 
   
M01 Antiinflammatory and antirheumatic products 6.0 2.5 
   
C07 Beta blocking agents 5.7 7.4 
   
N02 Analgesics 5.6 4.2 
   
A10 Drugs used in diabetes 4.7 4.3 
   
N05 Psycholeptics 4.5 3.8 
   
R03 Drugs for obstructive airways diseases  4.3 3.6 
   
A02 Drugs for acid related disorders  3.7 3.6 
   
C03 Diuretics 3.5 5.3 
   
N06 Psychoanaleptics 3.2 4.9 
   
H03 Thyroid therapy 3.2 2.5 
 
 
 
 
 
 
